Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling
By Aadel A Chaudhuri, J. Chabon, A. Lovejoy, Aaron M. Newman, H. Stehr, T. Azad, M. Khodadoust, M. S. Esfahani, C. Liu, Li Zhou and 17 more. Cancer Discovery, 2017
859 citations recorded by the source corpus.
Identifying molecular residual disease (MRD) after treatment of localized lung cancer could facilitate early intervention and personalization of adjuvant therapies. Here, we apply cancer personalized profi ling by deep sequencing (CAPP-seq) circulating tumor DNA (ctDNA) analysis to 255 samples from 40 patients treated with curative intent for stage I–III lung cancer and 54 healthy adults. In 94% of evaluable patients experiencing recurrence, ctDNA was detectable in the fi rst posttreatment blood sample, indicating reliable identifi cation of MRD. Posttreatment ctDNA detection preceded radiographic progression in 72% of patients by a median of 5.2 months, and 53% of patients harbored ctDNA mutation profi les associated with favorable responses to tyrosine kinase inhibitors or immune checkpoint blockade. Collectively, these results indicate that ctDNA MRD in patients with lung cancer can be accurately detected using CAPP-seq and may allow personalized adjuvant treatment while disease burden is lowest.
Subfields: Cancer Research, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/1d982e58e03af0535f67f70f55c0b76c063bdf39
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Pathology and Forensic Medicine
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments (2022, background): “Moreover, unlike CTCs, ctDNAs are known to act as biomarkers indicative of tumor volume, as revealed by studies in OVAC and lung cancer (LC) [117, 118].”
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer (2020, background): “Time to first recurrence, median (range), mo 22 (9-42) 22 (9-51)”
- Liquid Biopsy: From Discovery to Clinical Application. (2021, background): “Depending on the tumor type and stage, molecular relapse can be detected on average 2 to 9 months before imaging shows the conventional relapse (96, 97).”